Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Jun:248:42-52.
doi: 10.1016/j.ahj.2022.02.010. Epub 2022 Feb 24.

Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study

Affiliations
Randomized Controlled Trial

Randomized evaluation of decision support interventions for atrial fibrillation: Rationale and design of the RED-AF study

Aubrey E Jones et al. Am Heart J. 2022 Jun.

Abstract

Background: Shared decision making (SDM) improves the likelihood that patients will receive care in a manner consistent with their priorities. To facilitate SDM, decision aids (DA) are commonly used, both to prepare a patient before their clinician visit, as well as to facilitate discussion during the visit. However, the relative efficacy of patient-focused or encounter-based DAs on SDM and patient outcomes remains largely unknown. We aim to directly estimate the comparative effectiveness of two DA's on SDM observed in encounters to discuss stroke prevention strategies in patients with atrial fibrillation (AF).

Methods: The study aims to recruit 1200 adult patients with non-valvular AF who qualify for anticoagulation therapy, and their clinicians who manage stroke prevention strategies, in a 2x2 cluster randomized multi-center trial at six sites. Two DA's were developed as interactive, online, non-linear tools: a patient decision aid (PDA) to be used by patients before the encounter, and an encounter decision aid (EDA) to be used by clinicians with their patients during the encounter. Patients will be randomized to PDA or usual care; clinicians will be randomized to EDA or usual care.

Results: Primary outcomes are quality of SDM, patient decision making, and patient knowledge. Secondary outcomes include anticoagulation choice, adherence, and clinical events.

Conclusion: This trial is the first randomized, head-to-head comparison of the effects of an EDA versus a PDA on SDM. Our results will help to inform future SDM interventions to improve patients' AF outcomes and experiences with stroke prevention strategies.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest Dr Steinberg reports research support from Abbott, Cardiva, AltaThera, Boston Scientific, and Janssen; and consulting to Janssen, AltaThera, Merit Medical, and Crowley Fleck, LLP; and speaking for NACCME (funded by Sanofi). Dr Witt reports research support from and consulting to Roche Diagnostics. Dr Barnes reports consulting for Pfizer/Bristol-Myers Squibb, Janssen, and Acelis Connected Health. Dr Noseworthy is a study investigator in an ablation trial sponsored by Medtronic, is involved in potential equity/royalty relationship with AliveCor, has served on an expert advisory panel for Optum, and has filed patents related to the application of AI to the ECG for diagnosis and risk stratification.

Figures

Figure 1
Figure 1
Outline of Randomized Evaluation of Decision Support Interventions for Atrial Fibrillation (RED-AF) methodology design. EDA, encounter decision aid; EMR, electronic medical records; PDA, patient decision aid.

Similar articles

Cited by

References

    1. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370–5. - PubMed
    1. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. Circulation 2004;110:1042–6. - PubMed
    1. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534–9. - PubMed
    1. Go AS, Hylek EM, Chang Y, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003;290:2685–92. - PubMed
    1. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492–501. - PubMed

Publication types